Altair Engineering's ROCE trend is concerning, having declined over the past five years. Despite this, the stock has yielded a 124% return to long-term shareholders, reflecting market optimism. However, if these trends continue, it may not be a multi-bagger in the future.
Altair Engineering's high P/S ratio may not be justified due to weak revenue forecasts. This could pose a risk to shareholders and potential investors as it may negatively impact the share price.
Altair Engineering's revenue growth, reflected in its rising share price, is the market's focus due to lack of profits. Recent positive sentiment suggests potential business momentum.
$Altair Engineering(ALTR.US)$low Reward/Risk ratio not interested here. hit hard several stonks panic buying not considering R/R ratio . No more emotions attached to fear of missing plays in market. always careful 👍🏻
The recent selling of shares by insiders at Altair Engineering, without any recorded purchases, may raise concerns among shareholders. Despite the high level of insider ownership, the lack of buying activity does not inspire confidence in the company's prospects.
Investors: monitor for potential price drop due to current overvaluation. Current timing may not be ideal for entry due to surpassing of true value. However, optimistic outlook suggests looking into other factors for next price drop.
Upgrades •$Carvana(CVNA.US)$: Raymond James Upgrades to Market Perform from Underperform •$纽曼矿业(NEM.US)$: Canaccord Upgrades to Buy from Hold - PT $66 (from $60) •$印北瓦电(NI.US)$: Edward Jones Upgrades to Buy from Hold •$斯伦贝谢(SLB.US)$: Benchmark Upgrades to Buy from Hold - PT $55 Downgrades •$阿吉赛斯(AGYS.US)$: Craig-Hallum Downgrades to Hold from Buy •$克利夫兰克里夫(CLF.US)$: GLJ Research Downgrades t...
Gainers: •$Axsome Therapeutics(AXSM.US)$+39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder) •$Capricor Therapeutics(CAPR.US)$+4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
Altair Engineering股票讨论区
专栏Top upgrades and downgrades on 7/27: MCD, SHOP, SLB, LOGI and more
• $Carvana(CVNA.US)$ : Raymond James Upgrades to Market Perform from Underperform
• $纽曼矿业(NEM.US)$ : Canaccord Upgrades to Buy from Hold - PT $66 (from $60)
• $印北瓦电(NI.US)$ : Edward Jones Upgrades to Buy from Hold
• $斯伦贝谢(SLB.US)$ : Benchmark Upgrades to Buy from Hold - PT $55
Downgrades
• $阿吉赛斯(AGYS.US)$ : Craig-Hallum Downgrades to Hold from Buy
• $克利夫兰克里夫(CLF.US)$ : GLJ Research Downgrades t...
专栏Today's pre-market stock movers: BNTX, JBLU, DWAC, SAVE and more
• $Axsome Therapeutics(AXSM.US)$ +39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder)
• $Capricor Therapeutics(CAPR.US)$ +4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
专栏Top upgrades and downgrades on 6/27: ETSY, CHWY, BBBY, GTLB and more
• $汽车地带(AZO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $2,296 (from $1,969)
• $Chewy(CHWY.US)$ : Needham Upgrades to Buy from Hold - PT $55
• $National Vision(EYE.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $31)
• $费森尤斯医疗(FMS.US)$ : Jefferies Upgrades to Buy from Underperform - PT $33.70 (from $30.30)
• $Gitlab(GTLB.US)$ : Goldman Sachs Upgrades to Buy from Neutral - ...
专栏Top upgrades and downgrades on 11/05
By Mia
$Redbox Entertainment(RDBX.US)$$Altair Engineering(ALTR.US)$$加拿大贝尔(BCE.US)$$思佳讯(SWKS.US)$$再生元制药公司(REGN.US)$
暂无评论